Value-based oncology: care teams and technology that sit between patients, oncologists and health plans, paid on cost and outcomes.
Thyme Care is a Nashville oncology company that puts a care team and a technology layer between people with cancer, their oncologists and their health plans, and gets paid on total cost of care and outcomes rather than volume. Care teams support patients longitudinally, closing gaps between appointments, while the platform integrates into existing provider workflows and aligns clinical decisions with financial accountability. The company says its services reach more than 10.5 million people across all 50 states, that it manages more than $7 billion in oncology spend, and that it delivers validated 5 to 10 percent reductions in total cost of care. It was founded in 2020 by Robin Shah and Bobby Green, M.D.; alongside its September 2026 Series E it created Thyme Companies, a parent entity for further oncology businesses.
Healthcare📍 Nashville, TNFounded 2020
Current Valuation
$2.0B
as of 2026-09-02
UNICORN
QL Price
$2.0B
0% vs last round
QuantLogix's current estimate for Thyme Care, published 2026-09-14 — in line with the last disclosed round of $2.0B (2026-09-02).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$2.0B
2026-09-02
weight 0.98
How this price has held up
No round has priced for Thyme Care since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-14 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Thyme Care, 2026-09-14 (a9dd15240e5b78e3).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Thyme Care going public?
No. Thyme Care is private and has not filed to go public. There is no S-1 on file.
What is Thyme Care's valuation in 2026?
Thyme Care is valued at $2.0B as of 09/02/2026, set by its Series E ($125M, Sep 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Thyme Care filed an S-1?
No public S-1 is on file for Thyme Care.
Who are Thyme Care's investors?
Thyme Care's investors include Morgan Health, Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital and 4 more.
Can you buy Thyme Care stock?
No. Thyme Care is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Thyme Care on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Brad Diephuis, M.D.
Founded
2020
HQ
Nashville, TN
Growth
Services available to more than 10.5 million people across all 50 states, managing more than $7 billion in oncology spend, per the company's September 2026 release, which also states that Thyme Care is profitable and generates positive free cash flow. Earned NCQA accreditation for both its cancer case management and population health programs in 2026.
Last Round
Series E — $125M (Sep 2026) · Lead: Morgan Health
IPO Status
private
Fundraising Status
Series E · $125M · this month
private1 disclosed rounds
Series E Impact
Round Size
$125M
Primary financing announced
Post-Money Valuation
$2.0B
Company-announced mark
Round / Post-Money
6.3%
New capital ÷ post-money
Step-up compares disclosed post-money valuations. Round / post-money is a financing-size ratio, not an ownership or dilution estimate.
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series E
$125M
Sep 2026
Morgan Health
$2.0B
Talent Signal
Hiring data for Thyme Care has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Founders & Key People
Robin ShahBobby Green, M.D.
Investors
Morgan Health · Humana · CVS Health Ventures · AlleyCorp · HealthQuest Capital · Foresite Capital · Concord Health Partners · Frist Cressey Ventures · Town Hall Ventures · a16z Bio + Health
Products
Oncology care navigation — dedicated care teams (nurses, navigators, social workers) supporting patients longitudinally between visits, integrated into existing provider workflows
Value-based contracts with health plans and providers that tie payment to total cost of care and outcomes; the company reports 5 to 10 percent validated reductions in total cost of care
Technology platform connecting patients, oncologists and payers around a shared care model
Competitors
Jasper Health · Reimagine Care · OncoHealth · Carrum Health
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-09-02. Refreshed quarterly.